SummaryEligible participants will receive immunotherapy (cemiplimab) at a dose of 250mg intravenously every 3 weeks for up to 12 weeks. This study has primarily a translational research objective with the clinical component conducted as a prospective, single arm open label study.
Treatment TypeRadiotherapy,Systemic therapy (chemotherapy, hormone therapy or immunotherapy)
Use the hyperlinks, where available to access additional clinical trial information.
Peter MacCallum Cancer Centre
Comprehensive and Deep Profiling in Cutaneous Squamous Cell Carcinomas to Unravel Treatment Efficacy in Immunotherapy Treated Patients